home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap


UBBFriend: Email This Page to Someone!
  HUM-MOLGEN
  DIAGnostics - Clinical Research (professional requests)
  Open Enrollment for Relapsed DLBCL - A Phase IIb Vorinostat Study

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   Open Enrollment for Relapsed DLBCL - A Phase IIb Vorinostat Study
Administrator
Administrator
posted 07-17-2005 09:26 PM     Click Here to See the Profile for Administrator     Edit/Delete Message Reply w/Quote
Dear Colleague:

Merck & Co., Inc. is sponsoring a clinical trial for patients with relapsed Diffuse Large B Cell Lymphoma (DLBCL) throughout the United States and in selected ex-US countries.

This study is open to patients diagnosed with advanced Diffuse Large B Cell Lymphoma who have progressive, persistent, or recurrent disease following standard first line therapy with CHOP (or equivalent anthracycline-containing regimen) and at least one systemic salvage regimen (including but not limited to autologous hematopoietic stem cell transplant). All patients in this non-randomized, open-label, Phase IIb study will receive the oral histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid, SAHA).

In the United States, participating study sites are located in the following states:

Alabama
New Jersey
California
New York
Colorado
North Carolina
Connecticut
Pennsylvania
Illinois
Tennessee
Massachusetts
Texas
Michigan
Washington, DC
Nebraska

More information about this study can be found at: http://clinicaltrials.gov (Study ID: 2004_029 NCT00097929), or http://www.cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx (Protocol ID: 2004_029 )

To refer patients for evaluation for inclusion in this protocol,
please call 1-888-577-8839 (toll free).

Please feel free to forward this message to other health care providers who might be interested in learning more about the study and/or referring patients into this study.

Respectfully,

Sophia Randolph, M.D., Ph.D.
<merck@m3login.com>
Associate Director
Clinical Molecular Profiling
Merck & Co., Inc.

IP: 84.189.42.35

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2015

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.

By posting requests at HUM-MOLGEN you reach more than 9.500 mailing list subscribers and a 6 digit number of www users. Therefore post high quality messages only, including full name and institutional address.